Today's Rundown Roche promotes Pao to replace departing pRED head Reed Pfizer calls it quits on CytomX deal as research comes to naught JW Therapeutics, a China CAR-T biotech formed by Juno and WuXi, gains $90M series A Sanofi, Evotec in major infectious disease R&D transfer and license deal Merck KGaA BTK inhibitor beats placebo in phase 2 multiple sclerosis trial VBL Therapeutics sees Avastin-VB-111 phase 3 combo flop in brain cancer Parkinson’s startup Prevail raises $75M for gene therapy programs Cyteir reels in $29M to target DNA repair in cancer, autoimmune disease Helix to grow DNA test ‘app store’ on first close of planned $200M series B Featured Story | | | Thursday, March 8, 2018 John Reed, M.D., Ph.D., is leaving Roche for personal reasons. William Pao, M.D., Ph.D., has stepped up to fill the head of Roche pharma research and early development (pRED) post vacated by Reed. |
|
|
Top Stories Thursday, March 8, 2018 Pfizer has been slowly backing out of its $635 million armed antibody tech deal with CytomX over the last few months, and during the biotech’s financials posted late yesterday, the final nail was drilled into this fruitless pact. Thursday, March 8, 2018 Back in 2016, Juno Therapeutics (now owned by Celgene) and WuXi AppTec joined forces to create a new CAR-T biotech. Today, it got off a meaty $90 million series A with Chinese backing as it eyes clinical trials of its new cancer therapy. Thursday, March 8, 2018 Big Pharma Sanofi and German CRO-biotech drug discovery hybrid Evotec are penning a deal that will see Sanofi license out a host of infectious disease assets to the biotech, with 100 staffers also moving into its R&D engine. Thursday, March 8, 2018 A phase 2a trial of Merck KGaA’s BTK inhibitor evobrutinib has hit its primary endpoint. The prospect chalked up the win by reducing gadolinium-enhancing T1 lesions by more than placebo, but Merck has yet to quantify the difference or say how it fared against rival multiple sclerosis drug Tecfidera. Thursday, March 8, 2018 Israeli biotech VBL Therapeutics has joined a long and depressing line of companies that have failed to move the needle in a test against a form of aggressive brain tumor. Thursday, March 8, 2018 The biotech will use the funds to advance programs for Parkinson's and other neurodegenerative diseases caused by lysosomal dysfunction. Thursday, March 8, 2018 The funding will propel Cyteir's lead program, small-molecule RAD51 inhibitors, into clinical trials in cancer, as well as boost its preclinical work in autoimmune disease. Thursday, March 8, 2018 As next-generation technologies continue to drive down costs for DNA sequencing, DNA tests have become more accessible to the masses. Illumina spinout Helix, which runs an online marketplace for such tests, has held the first close of a planned $200 million funding round. | This week's sponsor is cobra:bio. | | | 1ml Long Syringe Line Now Available
In response to customer demand, Cobra has invested in an expansion of capabilities for batches up to 20k units. Today ~80% of the market for high value, low volume biologicals utilises the 1ml long format. More... |
Resources Sponsored by: MK&A There’s no magic bullet to successful access but insights from patient advocates and industry experts can help shape future strategies. Learn how in this webinar. Sign up now! Sponsored by: Reprints Desk The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market? Presented by: Box and USDM Life Sciences Learn how biopharma and medical device companies can now collaborate on, manage and distribute regulated clinical, lab and manufacturing content in Box. That means all of your content is standardized on a single content repository that meets regulatory and compliance standards, so you can eliminate inefficient silos, enable seamless collaboration and accelerate the validation process. Sponsored by: RBC Wealth Management Employee stock option trading & administration, Restricted stock transactions (Rule 144), Affiliated trading plans (10b5-1), Directed share plans, Equity comp plan administration — private to public Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Approval, Manufacturing Quality & Regulation 2018 | Online BioBasics: Biotech for the Non-Scientist March 29-30, 2018 | Boston, MA MIXiii-Biomed 2018 May 15-17, 2018 | Tel-Aviv, Israel Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! |
